View ValuationDexxos Participações 향후 성장Future 기준 점검 1/6Dexxos Participações은 연간 수입과 매출이 각각 8.8%와 11% 증가할 것으로 예상되고 EPS는 연간 14.9%만큼 증가할 것으로 예상됩니다.핵심 정보8.8%이익 성장률14.86%EPS 성장률Chemicals 이익 성장68.8%매출 성장률11.0%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트12 May 2026최근 향후 성장 업데이트Major Estimate Revision • Nov 21Consensus EPS estimates increase by 17%, revenue downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from R$2.22b to R$2.08b. EPS estimate rose from R$1.24 to R$1.45. Net income forecast to grow 5.2% next year vs 31% growth forecast for Chemicals industry in Brazil. Consensus price target of R$12.00 unchanged from last update. Share price rose 2.9% to R$8.20 over the past week.Major Estimate Revision • Sep 16Consensus EPS estimates fall by 14%, revenue upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from R$2.08b to R$2.22b. EPS estimate fell from R$1.45 to R$1.24 per share. Net income forecast to shrink 13% next year vs 33% growth forecast for Chemicals industry in Brazil . Consensus price target of R$12.00 unchanged from last update. Share price was steady at R$8.44 over the past week.모든 업데이트 보기Recent updatesNew Risk • May 17New major risk - Revenue and earnings growthEarnings have declined by 2.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.3% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.분석 기사 • Apr 01Dexxos Participações' (BVMF:DEXP3) Solid Earnings May Rest On Weak FoundationsDexxos Participações S.A.'s ( BVMF:DEXP3 ) healthy profit numbers didn't contain any surprises for investors. We think...공시 • Mar 31Dexxos Participações S.A., Annual General Meeting, Apr 29, 2026Dexxos Participações S.A., Annual General Meeting, Apr 29, 2026. Location: hotel windsor guanabara. av. presidente vargas 392, 4 andar, sala guanabara iii, centro, city and state of rio de janeiro., rio de janeiro. BrazilReported Earnings • Mar 27Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: EPS: R$1.33. Revenue: R$2.14b (up 18% from FY 2024). Net income: R$143.7m (flat on FY 2024). Profit margin: 6.7% (down from 8.0% in FY 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) exceeded analyst estimates by 7.3%. Revenue is forecast to grow 2.1% p.a. on average during the next 2 years, compared to a 4.8% growth forecast for the Chemicals industry in South America.New Risk • Mar 26New major risk - Revenue and earnings growthEarnings have declined by 0.05% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.05% per year over the past 5 years. Minor Risk Dividend is not well covered by cash flows (284% cash payout ratio).Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Frederico Atila Neves was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Major Estimate Revision • Nov 21Consensus EPS estimates increase by 17%, revenue downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from R$2.22b to R$2.08b. EPS estimate rose from R$1.24 to R$1.45. Net income forecast to grow 5.2% next year vs 31% growth forecast for Chemicals industry in Brazil. Consensus price target of R$12.00 unchanged from last update. Share price rose 2.9% to R$8.20 over the past week.Reported Earnings • Nov 17Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: R$516.7m (up 4.6% from 3Q 2024). Net income: R$29.5m (down 23% from 3Q 2024). Profit margin: 5.7% (down from 7.8% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 5% per year.Buy Or Sell Opportunity • Nov 06Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.6% to R$7.88. The fair value is estimated to be R$9.86, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.5% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 6.6% in 2 years. Earnings are forecast to decline by 3.8% in the next 2 years.Major Estimate Revision • Sep 16Consensus EPS estimates fall by 14%, revenue upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from R$2.08b to R$2.22b. EPS estimate fell from R$1.45 to R$1.24 per share. Net income forecast to shrink 13% next year vs 33% growth forecast for Chemicals industry in Brazil . Consensus price target of R$12.00 unchanged from last update. Share price was steady at R$8.44 over the past week.Buy Or Sell Opportunity • Aug 29Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to R$8.34. The fair value is estimated to be R$10.70, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.5% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 0.4% in 2 years. Earnings are forecast to grow by 4.1% in the next 2 years.Reported Earnings • Aug 13Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: R$597.3m (up 36% from 2Q 2024). Net income: R$38.9m (up 29% from 2Q 2024). Profit margin: 6.5% (down from 6.9% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in South America.Buy Or Sell Opportunity • Aug 12Now 21% undervaluedOver the last 90 days, the stock has risen 9.0% to R$8.44. The fair value is estimated to be R$10.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.6% over the last 3 years. Earnings per share has declined by 5.3%. Revenue is forecast to grow by 7.5% in 2 years. Earnings are forecast to grow by 8.4% in the next 2 years.Buy Or Sell Opportunity • Jul 18Now 21% undervaluedOver the last 90 days, the stock has risen 11% to R$8.67. The fair value is estimated to be R$10.91, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.6% over the last 3 years. Earnings per share has declined by 5.3%. Revenue is forecast to grow by 7.5% in 2 years. Earnings are forecast to grow by 8.4% in the next 2 years.Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to R$9.44, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 15x in the Chemicals industry globally. Total returns to shareholders of 17% over the past three years.분석 기사 • May 22Dexxos Participações' (BVMF:DEXP3) Sluggish Earnings Might Be Just The Beginning Of Its ProblemsDespite Dexxos Participações S.A.'s ( BVMF:DEXP3 ) recent earnings report having lackluster headline numbers, the...Reported Earnings • May 17First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: R$603.2m (up 56% from 1Q 2024). Net income: R$52.6m (up 30% from 1Q 2024). Profit margin: 8.7% (down from 10% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.3% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Chemicals industry in South America.공시 • Mar 27Dexxos Participações S.A., Annual General Meeting, Apr 28, 2025Dexxos Participações S.A., Annual General Meeting, Apr 28, 2025. Location: hotel windsor guanabara. av. presidente vargas 392, 3 andar, sala pancetti, centro, rio de janeiro. BrazilReported Earnings • Mar 26Full year 2024 earnings: Revenues exceed analyst expectationsFull year 2024 results: Revenue: R$1.81b (up 3.7% from FY 2023). Net income: R$144.2m (down 20% from FY 2023). Profit margin: 8.0% (down from 10% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 3% per year.New Risk • Mar 17New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 6.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (16% increase in shares outstanding).분석 기사 • Jan 21These 4 Measures Indicate That Dexxos Participações (BVMF:DEXP3) Is Using Debt Reasonably WellLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Nov 18Dexxos Participações (BVMF:DEXP3) Strong Profits May Be Masking Some Underlying IssuesThe stock price didn't jump after Dexxos Participações S.A. ( BVMF:DEXP3 ) posted decent earnings last week. Our...Reported Earnings • Nov 13Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: R$494.1m (up 20% from 3Q 2023). Net income: R$38.5m (down 3.6% from 3Q 2023). Profit margin: 7.8% (down from 9.7% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 7.0% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 3% per year.New Risk • Aug 16New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (16% increase in shares outstanding).Reported Earnings • Aug 11Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: R$438.9m (flat on 2Q 2023). Net income: R$30.1m (down 26% from 2Q 2023). Profit margin: 6.9% (down from 9.2% in 2Q 2023). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 7.4% growth forecast for the Global Chemicals industry. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 9% per year.Reported Earnings • May 12First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: R$387.9m (down 17% from 1Q 2023). Net income: R$40.4m (down 11% from 1Q 2023). Profit margin: 10% (in line with 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 5.8% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 5% per year.분석 기사 • Apr 01Dexxos Participações' (BVMF:DEXP3) Solid Earnings Have Been Accounted For ConservativelyThe market seemed underwhelmed by the solid earnings posted by Dexxos Participações S.A. ( BVMF:DEXP3 ) recently. Our...Reported Earnings • Mar 26Full year 2023 earnings releasedFull year 2023 results: Revenue: R$1.75b (down 17% from FY 2022). Net income: R$180.8m (up 21% from FY 2022). Profit margin: 10% (up from 7.1% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 9.6% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in South America.분석 기사 • Nov 11Dexxos Participações (BVMF:DEXP3) Is Very Good At Capital AllocationIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...공시 • Aug 18Dexxos Participações S.A. to Report Q3, 2023 Results on Nov 09, 2023Dexxos Participações S.A. announced that they will report Q3, 2023 results on Nov 09, 2023Valuation Update With 7 Day Price Move • Aug 17Investor sentiment improves as stock rises 18%After last week's 18% share price gain to R$11.05, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 14x in the Chemicals industry globally. Total returns to shareholders of 254% over the past three years.Reported Earnings • Aug 11Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: R$442.7m (down 20% from 2Q 2022). Net income: R$40.8m (up 36% from 2Q 2022). Profit margin: 9.2% (up from 5.4% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 1.6% growth forecast for the Chemicals industry in South America.Reported Earnings • May 14First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: R$469.1m (down 24% from 1Q 2022). Net income: R$45.6m (down 22% from 1Q 2022). Profit margin: 9.7% (in line with 1Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 3.2% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 85% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • May 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to R$9.40, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 13x in the Chemicals industry globally. Total returns to shareholders of 588% over the past three years.분석 기사 • Mar 30Why We Like The Returns At Dexxos Participações (BVMF:DEXP3)Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Reported Earnings • Mar 30Full year 2022 earnings: Revenues miss analyst expectationsFull year 2022 results: Revenue: R$2.10b (up 18% from FY 2021). Net income: R$149.9m (down 22% from FY 2021). Profit margin: 7.1% (down from 11% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 7.0%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, while revenues in the Chemicals industry in South America are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • Jan 26Should You Investigate Dexxos Participações S.A. (BVMF:DEXP3) At R$8.07?While Dexxos Participações S.A. ( BVMF:DEXP3 ) might not be the most widely known stock at the moment, it received a...Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Amin Murad is the most experienced director on the board, commencing their role in 2019. Independent Director Fernando Furtado was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Valuation Update With 7 Day Price Move • Nov 11Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to R$7.71, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 7x in the Chemicals industry in South America. Total returns to shareholders of 284% over the past three years.분석 기사 • Oct 26Do Dexxos Participações' (BVMF:DEXP3) Earnings Warrant Your Attention?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Valuation Update With 7 Day Price Move • Oct 07Investor sentiment improved over the past weekAfter last week's 18% share price gain to R$7.00, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 5x in the Chemicals industry in South America. Total returns to shareholders of 311% over the past three years.분석 기사 • Sep 06Is Dexxos Participações (BVMF:DEXP3) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Aug 15Under The Bonnet, Dexxos Participações' (BVMF:DEXP3) Returns Look ImpressiveTo find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...Reported Earnings • Aug 13Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: R$556.1m (up 33% from 2Q 2021). Net income: R$30.0m (down 55% from 2Q 2021). Profit margin: 5.4% (down from 16% in 2Q 2021). Over the next year, revenue is forecast to grow 7.4% compared to a 2.7% decline forecast for the industry in Brazil. Over the last 3 years on average, earnings per share has increased by 71% per year whereas the company’s share price has increased by 69% per year.Valuation Update With 7 Day Price Move • Jun 13Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to R$7.77, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 14x in the Chemicals industry globally. Total returns to shareholders of 1,061% over the past three years.분석 기사 • Jun 11At R$8.17, Is Dexxos Participações S.A. (BVMF:DEXP3) Worth Looking At Closely?Dexxos Participações S.A. ( BVMF:DEXP3 ), might not be a large cap stock, but it saw a decent share price growth in the...Valuation Update With 7 Day Price Move • May 20Investor sentiment improved over the past weekAfter last week's 16% share price gain to R$8.82, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 13x in the Chemicals industry globally. Total returns to shareholders of 1,060% over the past three years.분석 기사 • May 17We Think Dexxos Participações (BVMF:DEXP3) Can Stay On Top Of Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Board Change • Apr 27Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. 2 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Amin Murad is the most experienced director on the board, commencing their role in 2019. Independent Director Fernando Furtado was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.분석 기사 • Apr 12Returns On Capital Are A Standout For Dexxos Participações (BVMF:DEXP3)What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...Valuation Update With 7 Day Price Move • Mar 23Investor sentiment improved over the past weekAfter last week's 19% share price gain to R$10.41, the stock trades at a trailing P/E ratio of 4.9x. Average trailing P/E is 5x in the Chemicals industry in Brazil. Total returns to shareholders of 1,328% over the past three years.분석 기사 • Jan 26Here's Why I Think Dexxos Participações (BVMF:DEXP3) Might Deserve Your Attention TodayFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Valuation Update With 7 Day Price Move • Jan 08Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to R$8.82, the stock trades at a trailing P/E ratio of 4.2x. Average trailing P/E is 6x in the Chemicals industry in Brazil. Total returns to shareholders of 1,326% over the past three years.분석 기사 • Jan 05Dexxos Participações (BVMF:DEXP3) Knows How To Allocate Capital EffectivelyIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improved over the past weekAfter last week's 22% share price gain to R$9.80, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 6x in the Chemicals industry in Brazil. Total returns to shareholders of 1,577% over the past three years.분석 기사 • Dec 07Dexxos Participações (BVMF:DEXP3) Has A Pretty Healthy Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS R$0.73 (vs R$0.23 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: R$453.6m (up 57% from 3Q 2020). Net income: R$68.1m (up 213% from 3Q 2020). Profit margin: 15% (up from 7.6% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has increased by 134% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Nov 11Investor sentiment improved over the past weekAfter last week's 18% share price gain to R$10.01, the stock trades at a trailing P/E ratio of 6.2x. Average trailing P/E is 8x in the Chemicals industry in Brazil. Total returns to shareholders of 1,227% over the past three years.Valuation Update With 7 Day Price Move • Oct 23Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to R$9.89, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 8x in the Chemicals industry in Brazil. Total returns to shareholders of 1,190% over the past three years.분석 기사 • Oct 22Here's Why I Think Dexxos Participações (BVMF:DEXP3) Is An Interesting StockSome have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...분석 기사 • Sep 05Dexxos Participações (BVMF:DEXP3) Seems To Use Debt Quite SensiblyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Reported Earnings • Aug 14Second quarter 2021 earnings released: EPS R$0.71 (vs R$0.68 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: R$417.5m (up 111% from 2Q 2020). Net income: R$66.5m (up 4.1% from 2Q 2020). Profit margin: 16% (down from 32% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has increased by 167% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • Aug 07Dexxos Participações (BVMF:DEXP3) Is Achieving High Returns On Its CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...Valuation Update With 7 Day Price Move • Aug 06Investor sentiment improved over the past weekAfter last week's 15% share price gain to R$47.90, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 12x in the Chemicals industry in South America. Total returns to shareholders of 2,228% over the past three years.Valuation Update With 7 Day Price Move • Jun 17Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to R$43.73, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 11x in the Chemicals industry in South America. Total returns to shareholders of 1,701% over the past three years.Reported Earnings • Jun 06First quarter 2021 earnings released: EPS R$1.29 (vs R$0.37 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: R$345.4m (up 50% from 1Q 2020). Net income: R$40.4m (up 250% from 1Q 2020). Profit margin: 12% (up from 5.0% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 189% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improved over the past weekAfter last week's 24% share price gain to R$46.49, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 12x in the Chemicals industry in South America. Total returns to shareholders of 2,022% over the past three years.분석 기사 • May 27If You Like EPS Growth Then Check Out GPC Participações (BVMF:DEXP3) Before It's Too LateFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Reported Earnings • May 21First quarter 2021 earnings released: EPS R$1.30 (vs R$0.37 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: R$345.4m (up 50% from 1Q 2020). Net income: R$40.4m (up 250% from 1Q 2020). Profit margin: 12% (up from 5.0% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 145% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • May 10We Think GPC Participações (BVMF:GPCP3) Can Stay On Top Of Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Valuation Update With 7 Day Price Move • May 04Investor sentiment improved over the past weekAfter last week's 18% share price gain to R$35.40, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 14x in the Chemicals industry in South America. Total returns to shareholders of 1,291% over the past three years.Upcoming Dividend • Apr 25Upcoming dividend of R$0.84 per shareEligible shareholders must have bought the stock before 29 April 2021. Payment date: 31 December 2021. Trailing yield: 2.7%. Lower than top quartile of Brazilian dividend payers (4.9%). Lower than average of industry peers (3.9%).Valuation Update With 7 Day Price Move • Apr 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to R$24.30, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 14x in the Chemicals industry in South America. Total returns to shareholders of 875% over the past three years.분석 기사 • Apr 02The Attractive Combination That Could Earn GPC Participações S.A. (BVMF:GPCP3) A Place In Your Dividend PortfolioIs GPC Participações S.A. ( BVMF:GPCP3 ) a good dividend stock? How can we tell? Dividend paying companies with growing...Reported Earnings • Mar 23Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: R$994.7m (up 25% from FY 2019). Net income: R$119.2m (up 378% from FY 2019). Profit margin: 12% (up from 3.1% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 112% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Mar 16Investor sentiment improved over the past weekAfter last week's 23% share price gain to R$24.57, the stock trades at a trailing P/E ratio of 7.8x, up from the previous P/E ratio of 6.4x. Average P/E is 13x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 814%.Valuation Update With 7 Day Price Move • Feb 27Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to R$20.10, the stock is trading at a trailing P/E ratio of 6.4x, down from the previous P/E ratio of 7.6x. This compares to an average P/E of 12x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 634%.분석 기사 • Feb 26Are Strong Financial Prospects The Force That Is Driving The Momentum In GPC Participações S.A.'s BVMF:GPCP3) Stock?GPC Participações (BVMF:GPCP3) has had a great run on the share market with its stock up by a significant 26% over the...분석 기사 • Feb 05Do Institutions Own GPC Participações S.A. (BVMF:GPCP3) Shares?The big shareholder groups in GPC Participações S.A. ( BVMF:GPCP3 ) have power over the company. Generally speaking, as...분석 기사 • Jan 18Does GPC Participações (BVMF:GPCP3) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Valuation Update With 7 Day Price Move • Jan 11Investor sentiment improved over the past weekAfter last week's 17% share price gain to R$25.85, the stock is trading at a trailing P/E ratio of 13.2x, up from the previous P/E ratio of 11.3x. This compares to an average P/E of 12x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 774%.분석 기사 • Jan 01GPC Participações (BVMF:GPCP3) Is Growing Earnings But Are They A Good Guide?Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 20% share price gain to R$22.70, the stock is trading at a trailing P/E ratio of 11.6x, up from the previous P/E ratio of 9.6x. This compares to an average P/E of 11x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 659%.Is New 90 Day High Low • Dec 29New 90-day high: R$22.70The company is up 18% from its price of R$19.26 on 30 September 2020. The Brazilian market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 61% over the same period.Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improved over the past weekAfter last week's 16% share price gain to R$20.45, the stock is trading at a trailing P/E ratio of 10.4x, up from the previous P/E ratio of 9x. This compares to an average P/E of 10x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 584%.분석 기사 • Dec 14Is There More Growth In Store For GPC Participações' (BVMF:GPCP3) Returns On Capital?Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...분석 기사 • Nov 26Shareholders of GPC Participações (BVMF:GPCP3) Must Be Delighted With Their 884% Total ReturnBuying shares in the best businesses can build meaningful wealth for you and your family. While the best companies are...Valuation Update With 7 Day Price Move • Nov 19Market pulls back on stock over the past weekAfter last week's 21% share price decline to R$17.00, the stock is trading at a trailing P/E ratio of 8.7x, down from the previous P/E ratio of 11x. This compares to an average P/E of 12x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 574%.Reported Earnings • Oct 22Third quarter earnings releasedOver the last 12 months the company has reported total profits of R$98.2m, up 234% from the prior year. Total revenue was R$915.1m over the last 12 months, up 15% from the prior year.Valuation Update With 7 Day Price Move • Oct 17Market bids up stock over the past weekAfter last week's 15% share price gain to R$19.75, the stock is trading at a trailing P/E ratio of 7.1x, up from the previous P/E ratio of 6.1x. This compares to an average P/E of 9x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 719%.Is New 90 Day High Low • Sep 19New 90-day high: R$21.67The company is up 233% from its price of R$6.50 on 19 June 2020. The Brazilian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 26% over the same period.분석 기사 • Aug 12Can You Imagine How Jubilant GPC Participações' (BVMF:GPCP3) Shareholders Feel About Its 297% Share Price Gain?The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...분석 기사 • Aug 12Announcing: GPC Participações (BVMF:GPCP3) Stock Increased An Energizing 297% In The Last Three YearsThe most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...분석 기사 • Jul 13Investors Don't See Light At End Of GPC Participações S.A.'s (BVMF:GPCP3) TunnelWith a price-to-earnings (or "P/E") ratio of 9.6x GPC Participações S.A. (BVMF:GPCP3) may be sending bullish signals...분석 기사 • Jul 02Has GPC Participações S.A.'s (BVMF:GPCP3) Impressive Stock Performance Got Anything to Do With Its Fundamentals?GPC Participações''s (BVMF:GPCP3) stock is up by a considerable 50% over the past three months. We wonder if and what...이익 및 매출 성장 예측BOVESPA:DEXP3 - 애널리스트 향후 추정치 및 과거 재무 데이터 (BRL Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20272,360166N/A189112/31/20262,296152N/A17013/31/20261,921142184251N/A12/31/20252,137144165225N/A9/30/20252,2071564098N/A6/30/20252,184165-71-15N/A3/31/20252,026156-3353N/A12/31/20241,810144-1375N/A9/30/20241,74316479159N/A6/30/20241,660165177246N/A3/31/20241,664176240275N/A12/31/20231,745181315340N/A9/30/20231,801160324352N/A6/30/20231,840148313345N/A3/31/20231,953137186227N/A12/31/20222,098150159202N/A9/30/20222,1781343685N/A6/30/20222,182173-1738N/A3/31/20222,043210-3516N/A12/31/20211,774192-100-48N/A9/30/20211,494197-386N/A6/30/20211,328151-47-16N/A3/31/20211,1091486287N/A12/31/202099511993116N/A9/30/20209159892102N/A6/30/20208428887109N/A3/31/202084828-125N/A12/31/201979825N/A1N/A9/30/201979429N/A31N/A6/30/201976923N/A-2N/A3/31/20197288N/A-6N/A12/31/20187357N/A11N/A9/30/201867988N/A-69N/A6/30/201861389N/A-38N/A3/31/201856191N/A-5N/A12/31/201748481N/A-9N/A9/30/201744561N/A61N/A6/30/201743341N/A48N/A3/31/201743847N/A40N/A12/31/201643853N/A39N/A9/30/2016437-25N/A34N/A6/30/2016428-28N/A39N/A3/31/2016411-38N/A32N/A12/31/2015398-41N/A36N/A9/30/2015390-23N/A23N/A6/30/2015376-15N/A17N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: DEXP3 의 연간 예상 수익 증가율(8.8%)이 saving rate(12.4%) 미만입니다.수익 vs 시장: DEXP3 의 연간 수익(8.8%)이 BR 시장(12.9%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: DEXP3 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: DEXP3 의 수익(연간 11%)이 BR 시장(연간 6.9%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: DEXP3 의 수익(연간 11%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: DEXP3의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/11 20:12종가2026/06/10 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Dexxos Participações S.A.는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Carlos Palhares SequeiraBTG PactualRodrigo Reis de AlmeidaBTG Pactual
Major Estimate Revision • Nov 21Consensus EPS estimates increase by 17%, revenue downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from R$2.22b to R$2.08b. EPS estimate rose from R$1.24 to R$1.45. Net income forecast to grow 5.2% next year vs 31% growth forecast for Chemicals industry in Brazil. Consensus price target of R$12.00 unchanged from last update. Share price rose 2.9% to R$8.20 over the past week.
Major Estimate Revision • Sep 16Consensus EPS estimates fall by 14%, revenue upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from R$2.08b to R$2.22b. EPS estimate fell from R$1.45 to R$1.24 per share. Net income forecast to shrink 13% next year vs 33% growth forecast for Chemicals industry in Brazil . Consensus price target of R$12.00 unchanged from last update. Share price was steady at R$8.44 over the past week.
New Risk • May 17New major risk - Revenue and earnings growthEarnings have declined by 2.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.3% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
분석 기사 • Apr 01Dexxos Participações' (BVMF:DEXP3) Solid Earnings May Rest On Weak FoundationsDexxos Participações S.A.'s ( BVMF:DEXP3 ) healthy profit numbers didn't contain any surprises for investors. We think...
공시 • Mar 31Dexxos Participações S.A., Annual General Meeting, Apr 29, 2026Dexxos Participações S.A., Annual General Meeting, Apr 29, 2026. Location: hotel windsor guanabara. av. presidente vargas 392, 4 andar, sala guanabara iii, centro, city and state of rio de janeiro., rio de janeiro. Brazil
Reported Earnings • Mar 27Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: EPS: R$1.33. Revenue: R$2.14b (up 18% from FY 2024). Net income: R$143.7m (flat on FY 2024). Profit margin: 6.7% (down from 8.0% in FY 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) exceeded analyst estimates by 7.3%. Revenue is forecast to grow 2.1% p.a. on average during the next 2 years, compared to a 4.8% growth forecast for the Chemicals industry in South America.
New Risk • Mar 26New major risk - Revenue and earnings growthEarnings have declined by 0.05% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.05% per year over the past 5 years. Minor Risk Dividend is not well covered by cash flows (284% cash payout ratio).
Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Frederico Atila Neves was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Major Estimate Revision • Nov 21Consensus EPS estimates increase by 17%, revenue downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from R$2.22b to R$2.08b. EPS estimate rose from R$1.24 to R$1.45. Net income forecast to grow 5.2% next year vs 31% growth forecast for Chemicals industry in Brazil. Consensus price target of R$12.00 unchanged from last update. Share price rose 2.9% to R$8.20 over the past week.
Reported Earnings • Nov 17Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: R$516.7m (up 4.6% from 3Q 2024). Net income: R$29.5m (down 23% from 3Q 2024). Profit margin: 5.7% (down from 7.8% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 5% per year.
Buy Or Sell Opportunity • Nov 06Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.6% to R$7.88. The fair value is estimated to be R$9.86, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.5% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 6.6% in 2 years. Earnings are forecast to decline by 3.8% in the next 2 years.
Major Estimate Revision • Sep 16Consensus EPS estimates fall by 14%, revenue upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from R$2.08b to R$2.22b. EPS estimate fell from R$1.45 to R$1.24 per share. Net income forecast to shrink 13% next year vs 33% growth forecast for Chemicals industry in Brazil . Consensus price target of R$12.00 unchanged from last update. Share price was steady at R$8.44 over the past week.
Buy Or Sell Opportunity • Aug 29Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to R$8.34. The fair value is estimated to be R$10.70, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.5% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 0.4% in 2 years. Earnings are forecast to grow by 4.1% in the next 2 years.
Reported Earnings • Aug 13Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: R$597.3m (up 36% from 2Q 2024). Net income: R$38.9m (up 29% from 2Q 2024). Profit margin: 6.5% (down from 6.9% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in South America.
Buy Or Sell Opportunity • Aug 12Now 21% undervaluedOver the last 90 days, the stock has risen 9.0% to R$8.44. The fair value is estimated to be R$10.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.6% over the last 3 years. Earnings per share has declined by 5.3%. Revenue is forecast to grow by 7.5% in 2 years. Earnings are forecast to grow by 8.4% in the next 2 years.
Buy Or Sell Opportunity • Jul 18Now 21% undervaluedOver the last 90 days, the stock has risen 11% to R$8.67. The fair value is estimated to be R$10.91, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.6% over the last 3 years. Earnings per share has declined by 5.3%. Revenue is forecast to grow by 7.5% in 2 years. Earnings are forecast to grow by 8.4% in the next 2 years.
Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to R$9.44, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 15x in the Chemicals industry globally. Total returns to shareholders of 17% over the past three years.
분석 기사 • May 22Dexxos Participações' (BVMF:DEXP3) Sluggish Earnings Might Be Just The Beginning Of Its ProblemsDespite Dexxos Participações S.A.'s ( BVMF:DEXP3 ) recent earnings report having lackluster headline numbers, the...
Reported Earnings • May 17First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: R$603.2m (up 56% from 1Q 2024). Net income: R$52.6m (up 30% from 1Q 2024). Profit margin: 8.7% (down from 10% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.3% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Chemicals industry in South America.
공시 • Mar 27Dexxos Participações S.A., Annual General Meeting, Apr 28, 2025Dexxos Participações S.A., Annual General Meeting, Apr 28, 2025. Location: hotel windsor guanabara. av. presidente vargas 392, 3 andar, sala pancetti, centro, rio de janeiro. Brazil
Reported Earnings • Mar 26Full year 2024 earnings: Revenues exceed analyst expectationsFull year 2024 results: Revenue: R$1.81b (up 3.7% from FY 2023). Net income: R$144.2m (down 20% from FY 2023). Profit margin: 8.0% (down from 10% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 3% per year.
New Risk • Mar 17New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 6.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (16% increase in shares outstanding).
분석 기사 • Jan 21These 4 Measures Indicate That Dexxos Participações (BVMF:DEXP3) Is Using Debt Reasonably WellLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
분석 기사 • Nov 18Dexxos Participações (BVMF:DEXP3) Strong Profits May Be Masking Some Underlying IssuesThe stock price didn't jump after Dexxos Participações S.A. ( BVMF:DEXP3 ) posted decent earnings last week. Our...
Reported Earnings • Nov 13Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: R$494.1m (up 20% from 3Q 2023). Net income: R$38.5m (down 3.6% from 3Q 2023). Profit margin: 7.8% (down from 9.7% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 7.0% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 3% per year.
New Risk • Aug 16New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (16% increase in shares outstanding).
Reported Earnings • Aug 11Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: R$438.9m (flat on 2Q 2023). Net income: R$30.1m (down 26% from 2Q 2023). Profit margin: 6.9% (down from 9.2% in 2Q 2023). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 7.4% growth forecast for the Global Chemicals industry. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 9% per year.
Reported Earnings • May 12First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: R$387.9m (down 17% from 1Q 2023). Net income: R$40.4m (down 11% from 1Q 2023). Profit margin: 10% (in line with 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 5.8% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 5% per year.
분석 기사 • Apr 01Dexxos Participações' (BVMF:DEXP3) Solid Earnings Have Been Accounted For ConservativelyThe market seemed underwhelmed by the solid earnings posted by Dexxos Participações S.A. ( BVMF:DEXP3 ) recently. Our...
Reported Earnings • Mar 26Full year 2023 earnings releasedFull year 2023 results: Revenue: R$1.75b (down 17% from FY 2022). Net income: R$180.8m (up 21% from FY 2022). Profit margin: 10% (up from 7.1% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 9.6% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in South America.
분석 기사 • Nov 11Dexxos Participações (BVMF:DEXP3) Is Very Good At Capital AllocationIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
공시 • Aug 18Dexxos Participações S.A. to Report Q3, 2023 Results on Nov 09, 2023Dexxos Participações S.A. announced that they will report Q3, 2023 results on Nov 09, 2023
Valuation Update With 7 Day Price Move • Aug 17Investor sentiment improves as stock rises 18%After last week's 18% share price gain to R$11.05, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 14x in the Chemicals industry globally. Total returns to shareholders of 254% over the past three years.
Reported Earnings • Aug 11Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: R$442.7m (down 20% from 2Q 2022). Net income: R$40.8m (up 36% from 2Q 2022). Profit margin: 9.2% (up from 5.4% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 1.6% growth forecast for the Chemicals industry in South America.
Reported Earnings • May 14First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: R$469.1m (down 24% from 1Q 2022). Net income: R$45.6m (down 22% from 1Q 2022). Profit margin: 9.7% (in line with 1Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 3.2% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 85% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • May 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to R$9.40, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 13x in the Chemicals industry globally. Total returns to shareholders of 588% over the past three years.
분석 기사 • Mar 30Why We Like The Returns At Dexxos Participações (BVMF:DEXP3)Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Reported Earnings • Mar 30Full year 2022 earnings: Revenues miss analyst expectationsFull year 2022 results: Revenue: R$2.10b (up 18% from FY 2021). Net income: R$149.9m (down 22% from FY 2021). Profit margin: 7.1% (down from 11% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 7.0%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, while revenues in the Chemicals industry in South America are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • Jan 26Should You Investigate Dexxos Participações S.A. (BVMF:DEXP3) At R$8.07?While Dexxos Participações S.A. ( BVMF:DEXP3 ) might not be the most widely known stock at the moment, it received a...
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Amin Murad is the most experienced director on the board, commencing their role in 2019. Independent Director Fernando Furtado was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Valuation Update With 7 Day Price Move • Nov 11Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to R$7.71, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 7x in the Chemicals industry in South America. Total returns to shareholders of 284% over the past three years.
분석 기사 • Oct 26Do Dexxos Participações' (BVMF:DEXP3) Earnings Warrant Your Attention?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Valuation Update With 7 Day Price Move • Oct 07Investor sentiment improved over the past weekAfter last week's 18% share price gain to R$7.00, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 5x in the Chemicals industry in South America. Total returns to shareholders of 311% over the past three years.
분석 기사 • Sep 06Is Dexxos Participações (BVMF:DEXP3) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • Aug 15Under The Bonnet, Dexxos Participações' (BVMF:DEXP3) Returns Look ImpressiveTo find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...
Reported Earnings • Aug 13Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: R$556.1m (up 33% from 2Q 2021). Net income: R$30.0m (down 55% from 2Q 2021). Profit margin: 5.4% (down from 16% in 2Q 2021). Over the next year, revenue is forecast to grow 7.4% compared to a 2.7% decline forecast for the industry in Brazil. Over the last 3 years on average, earnings per share has increased by 71% per year whereas the company’s share price has increased by 69% per year.
Valuation Update With 7 Day Price Move • Jun 13Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to R$7.77, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 14x in the Chemicals industry globally. Total returns to shareholders of 1,061% over the past three years.
분석 기사 • Jun 11At R$8.17, Is Dexxos Participações S.A. (BVMF:DEXP3) Worth Looking At Closely?Dexxos Participações S.A. ( BVMF:DEXP3 ), might not be a large cap stock, but it saw a decent share price growth in the...
Valuation Update With 7 Day Price Move • May 20Investor sentiment improved over the past weekAfter last week's 16% share price gain to R$8.82, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 13x in the Chemicals industry globally. Total returns to shareholders of 1,060% over the past three years.
분석 기사 • May 17We Think Dexxos Participações (BVMF:DEXP3) Can Stay On Top Of Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Board Change • Apr 27Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. 2 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Amin Murad is the most experienced director on the board, commencing their role in 2019. Independent Director Fernando Furtado was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
분석 기사 • Apr 12Returns On Capital Are A Standout For Dexxos Participações (BVMF:DEXP3)What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...
Valuation Update With 7 Day Price Move • Mar 23Investor sentiment improved over the past weekAfter last week's 19% share price gain to R$10.41, the stock trades at a trailing P/E ratio of 4.9x. Average trailing P/E is 5x in the Chemicals industry in Brazil. Total returns to shareholders of 1,328% over the past three years.
분석 기사 • Jan 26Here's Why I Think Dexxos Participações (BVMF:DEXP3) Might Deserve Your Attention TodayFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to R$8.82, the stock trades at a trailing P/E ratio of 4.2x. Average trailing P/E is 6x in the Chemicals industry in Brazil. Total returns to shareholders of 1,326% over the past three years.
분석 기사 • Jan 05Dexxos Participações (BVMF:DEXP3) Knows How To Allocate Capital EffectivelyIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...
Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improved over the past weekAfter last week's 22% share price gain to R$9.80, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 6x in the Chemicals industry in Brazil. Total returns to shareholders of 1,577% over the past three years.
분석 기사 • Dec 07Dexxos Participações (BVMF:DEXP3) Has A Pretty Healthy Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS R$0.73 (vs R$0.23 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: R$453.6m (up 57% from 3Q 2020). Net income: R$68.1m (up 213% from 3Q 2020). Profit margin: 15% (up from 7.6% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has increased by 134% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Nov 11Investor sentiment improved over the past weekAfter last week's 18% share price gain to R$10.01, the stock trades at a trailing P/E ratio of 6.2x. Average trailing P/E is 8x in the Chemicals industry in Brazil. Total returns to shareholders of 1,227% over the past three years.
Valuation Update With 7 Day Price Move • Oct 23Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to R$9.89, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 8x in the Chemicals industry in Brazil. Total returns to shareholders of 1,190% over the past three years.
분석 기사 • Oct 22Here's Why I Think Dexxos Participações (BVMF:DEXP3) Is An Interesting StockSome have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
분석 기사 • Sep 05Dexxos Participações (BVMF:DEXP3) Seems To Use Debt Quite SensiblyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Reported Earnings • Aug 14Second quarter 2021 earnings released: EPS R$0.71 (vs R$0.68 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: R$417.5m (up 111% from 2Q 2020). Net income: R$66.5m (up 4.1% from 2Q 2020). Profit margin: 16% (down from 32% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has increased by 167% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • Aug 07Dexxos Participações (BVMF:DEXP3) Is Achieving High Returns On Its CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...
Valuation Update With 7 Day Price Move • Aug 06Investor sentiment improved over the past weekAfter last week's 15% share price gain to R$47.90, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 12x in the Chemicals industry in South America. Total returns to shareholders of 2,228% over the past three years.
Valuation Update With 7 Day Price Move • Jun 17Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to R$43.73, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 11x in the Chemicals industry in South America. Total returns to shareholders of 1,701% over the past three years.
Reported Earnings • Jun 06First quarter 2021 earnings released: EPS R$1.29 (vs R$0.37 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: R$345.4m (up 50% from 1Q 2020). Net income: R$40.4m (up 250% from 1Q 2020). Profit margin: 12% (up from 5.0% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 189% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improved over the past weekAfter last week's 24% share price gain to R$46.49, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 12x in the Chemicals industry in South America. Total returns to shareholders of 2,022% over the past three years.
분석 기사 • May 27If You Like EPS Growth Then Check Out GPC Participações (BVMF:DEXP3) Before It's Too LateFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Reported Earnings • May 21First quarter 2021 earnings released: EPS R$1.30 (vs R$0.37 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: R$345.4m (up 50% from 1Q 2020). Net income: R$40.4m (up 250% from 1Q 2020). Profit margin: 12% (up from 5.0% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 145% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • May 10We Think GPC Participações (BVMF:GPCP3) Can Stay On Top Of Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Valuation Update With 7 Day Price Move • May 04Investor sentiment improved over the past weekAfter last week's 18% share price gain to R$35.40, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 14x in the Chemicals industry in South America. Total returns to shareholders of 1,291% over the past three years.
Upcoming Dividend • Apr 25Upcoming dividend of R$0.84 per shareEligible shareholders must have bought the stock before 29 April 2021. Payment date: 31 December 2021. Trailing yield: 2.7%. Lower than top quartile of Brazilian dividend payers (4.9%). Lower than average of industry peers (3.9%).
Valuation Update With 7 Day Price Move • Apr 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to R$24.30, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 14x in the Chemicals industry in South America. Total returns to shareholders of 875% over the past three years.
분석 기사 • Apr 02The Attractive Combination That Could Earn GPC Participações S.A. (BVMF:GPCP3) A Place In Your Dividend PortfolioIs GPC Participações S.A. ( BVMF:GPCP3 ) a good dividend stock? How can we tell? Dividend paying companies with growing...
Reported Earnings • Mar 23Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: R$994.7m (up 25% from FY 2019). Net income: R$119.2m (up 378% from FY 2019). Profit margin: 12% (up from 3.1% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 112% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Mar 16Investor sentiment improved over the past weekAfter last week's 23% share price gain to R$24.57, the stock trades at a trailing P/E ratio of 7.8x, up from the previous P/E ratio of 6.4x. Average P/E is 13x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 814%.
Valuation Update With 7 Day Price Move • Feb 27Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to R$20.10, the stock is trading at a trailing P/E ratio of 6.4x, down from the previous P/E ratio of 7.6x. This compares to an average P/E of 12x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 634%.
분석 기사 • Feb 26Are Strong Financial Prospects The Force That Is Driving The Momentum In GPC Participações S.A.'s BVMF:GPCP3) Stock?GPC Participações (BVMF:GPCP3) has had a great run on the share market with its stock up by a significant 26% over the...
분석 기사 • Feb 05Do Institutions Own GPC Participações S.A. (BVMF:GPCP3) Shares?The big shareholder groups in GPC Participações S.A. ( BVMF:GPCP3 ) have power over the company. Generally speaking, as...
분석 기사 • Jan 18Does GPC Participações (BVMF:GPCP3) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Valuation Update With 7 Day Price Move • Jan 11Investor sentiment improved over the past weekAfter last week's 17% share price gain to R$25.85, the stock is trading at a trailing P/E ratio of 13.2x, up from the previous P/E ratio of 11.3x. This compares to an average P/E of 12x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 774%.
분석 기사 • Jan 01GPC Participações (BVMF:GPCP3) Is Growing Earnings But Are They A Good Guide?Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 20% share price gain to R$22.70, the stock is trading at a trailing P/E ratio of 11.6x, up from the previous P/E ratio of 9.6x. This compares to an average P/E of 11x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 659%.
Is New 90 Day High Low • Dec 29New 90-day high: R$22.70The company is up 18% from its price of R$19.26 on 30 September 2020. The Brazilian market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 61% over the same period.
Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improved over the past weekAfter last week's 16% share price gain to R$20.45, the stock is trading at a trailing P/E ratio of 10.4x, up from the previous P/E ratio of 9x. This compares to an average P/E of 10x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 584%.
분석 기사 • Dec 14Is There More Growth In Store For GPC Participações' (BVMF:GPCP3) Returns On Capital?Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
분석 기사 • Nov 26Shareholders of GPC Participações (BVMF:GPCP3) Must Be Delighted With Their 884% Total ReturnBuying shares in the best businesses can build meaningful wealth for you and your family. While the best companies are...
Valuation Update With 7 Day Price Move • Nov 19Market pulls back on stock over the past weekAfter last week's 21% share price decline to R$17.00, the stock is trading at a trailing P/E ratio of 8.7x, down from the previous P/E ratio of 11x. This compares to an average P/E of 12x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 574%.
Reported Earnings • Oct 22Third quarter earnings releasedOver the last 12 months the company has reported total profits of R$98.2m, up 234% from the prior year. Total revenue was R$915.1m over the last 12 months, up 15% from the prior year.
Valuation Update With 7 Day Price Move • Oct 17Market bids up stock over the past weekAfter last week's 15% share price gain to R$19.75, the stock is trading at a trailing P/E ratio of 7.1x, up from the previous P/E ratio of 6.1x. This compares to an average P/E of 9x in the Chemicals industry in South America. Total returns to shareholders over the past three years are 719%.
Is New 90 Day High Low • Sep 19New 90-day high: R$21.67The company is up 233% from its price of R$6.50 on 19 June 2020. The Brazilian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 26% over the same period.
분석 기사 • Aug 12Can You Imagine How Jubilant GPC Participações' (BVMF:GPCP3) Shareholders Feel About Its 297% Share Price Gain?The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
분석 기사 • Aug 12Announcing: GPC Participações (BVMF:GPCP3) Stock Increased An Energizing 297% In The Last Three YearsThe most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...
분석 기사 • Jul 13Investors Don't See Light At End Of GPC Participações S.A.'s (BVMF:GPCP3) TunnelWith a price-to-earnings (or "P/E") ratio of 9.6x GPC Participações S.A. (BVMF:GPCP3) may be sending bullish signals...
분석 기사 • Jul 02Has GPC Participações S.A.'s (BVMF:GPCP3) Impressive Stock Performance Got Anything to Do With Its Fundamentals?GPC Participações''s (BVMF:GPCP3) stock is up by a considerable 50% over the past three months. We wonder if and what...